| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | 0.0035 | 0.9 |
| mRNA | Crizotinib | gCSI | pan-cancer | AAC | 0.0054 | 0.9 |
| mRNA | BRD-K66532283 | CTRPv2 | pan-cancer | AAC | 0.0031 | 0.9 |
| mRNA | erismodegib | CTRPv2 | pan-cancer | AAC | -0.0035 | 0.9 |
| mRNA | JNK-9L | GDSC1000 | pan-cancer | AAC | -0.0033 | 0.9 |
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0032 | 0.9 |
| mRNA | purmorphamine | CTRPv2 | pan-cancer | AAC | -0.0034 | 0.9 |
| mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | 0.0027 | 0.9 |
| mRNA | YK 4-279 | CTRPv2 | pan-cancer | AAC | -0.0029 | 0.9 |
| mRNA | VX-680 | CTRPv2 | pan-cancer | AAC | 0.01 | 0.9 |